ArticlePloS one2018
Significant predictors of overall survival in patients with hepatocellular carcinoma after surgical resection.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 27 citations in OpenAlex.
- Survival Rate in Hepatocellular Carcinoma after Surgery and Its Association with Clinicopathological Factors: A Single-Center Report.Middle East journal of digestive diseases · 2025Article
- Determinants of Survival and Prognostic Factors in Patients Undergoing Liver Resection for Primary Hepatic Carcinoma-A Follow-Up Study.Clinics and practice · 2025Article
- The correlation between ALDH2 rs671 polymorphism and clinical prognosis in alcoholic liver disease-related hepatocellular carcinoma after curative resection.American journal of cancer research · 2025Article
- MR-linac based radiation therapy in gastrointestinal cancers: a narrative review.Journal of gastrointestinal oncology · 2024Review
- Unawareness of hepatitis B infection and lack of surveillance are associated with severity of hepatocellular carcinoma.The Kaohsiung journal of medical sciences · 2023Article
- NPRL2 down-regulation facilitates the growth of hepatocellular carcinoma via the mTOR pathway and autophagy suppression.Hepatology communications · 2022Article
- Serum Sorbitol Dehydrogenase as a Novel Prognostic Factor for Hepatocellular Carcinoma after Surgical Resection.Cancers · 2021Article
- Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma.Hepatology international · 2021Article
- Role of autophagy-related protein in the prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgical resection.BMC cancer · 2021Article
- Article
- Surgical resection significantly promotes the overall survival of patients with hepatocellular carcinoma: a propensity score matching analysis.BMC gastroenterology · 2021Article
- A New Clinical Nomogram From the TCGA Database to Predict the Prognosis of Hepatocellular Carcinoma.Frontiers in oncology · 2021Article
- MR-Guided Radiotherapy for Liver Malignancies.Frontiers in oncology · 2021Review
- Axl and autophagy LC3 expression in tumors is strongly associated with clinical prognosis of hepatocellular carcinoma patients after curative resection.Cancer medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe predictive factors of overall survival after hepatectomy for HCC remain controversial and need to be investigated.
methodsIn total, 535 consecutive HCC patients undergoing resection were included and their clinicopathological data and overall survival were recorded. Both the tumor and adjacent non-tumor (ANT) tissues were subjected to immunohistochemistry analysis for the expression of autophagy-related markers.
resultsDeath was observed for 219 patients, and the cumulative overall survival rates at 1, 3, 5 and 7 years were 91.0%, 72.3%, 58.8%, and 27.7%, respectively. In the multivariate analysis, mortality was significantly associated with the following: diminished LC3 expression in both the tumor and ANT tissues, in the HCC tissues alone and in the ANT tissues alone (hazard ratio/95% confidence interval: 6.74/2.052-22.19, 6.70/1.321-33.98 and 2.58/1.499-4.915, respectively); recurrent HCC (5.11/3.136-8.342); HBV infection (2.75/1.574-4.784); cirrhosis (1.78/1.059-2.974); and antiviral therapy (0.42/0.250-0.697). The 5-year overall survival rates were 70.2%, 57.3%, 49.6% and 10.7% for patients with positive LC3 expression in both tissue types, in the HCC tissues alone, in the ANT tissues alone, and in neither tissue type, respectively. The 5-year overall survival rates were 56.7%, 47.3%, 51.2% and 38.7% for patients with HBV-related HCC, cirrhosis, no antiviral therapy, and recurrent HCC, respectively, and these rates were significantly lower than those in their counterparts.
conclusionsPatients with recurrent HCC, HBV-related HCC, cirrhosis, and the absence of antiviral therapy showed significantly lower overall survival rates. Furthermore, LC3 expression in both the tumor and liver microenvironments were significantly predictive of overall survival after resection for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.